В Китае разгорелся скандал с некачественной вакциной. Завозят ли ее в Кыргызстан?

5337  3

В Китае обнаружили непригодные для использования вакцины: крупнейший производитель нарушил стандарты по их изготовлению. Об этом сообщают СМИ.

Отмечено, что компания "Чангчун Чангшенг" изготовила не менее 250 тысяч вакцин без соблюдения надлежащих стандартов. Китайцы жалуются на то, что коррупция и злоупотребления в фармацевтической отрасли страны ставят под угрозу жизни простых людей.

Скандал привел к массовым критическим сообщениям в интернете в адрес китайского правительства и пошатнул доверие к нему. Там опасаются, что родители массово начнут отказываться вакцинировать своих детей, хотя это и предусмотрено законом.

Может ли некачественная вакцина повредить кыргызстанским детям?

Как прокомментировала Kaktus.media директор Республиканского центра иммунопрофилактики Гульбара Ишенапысова, в Кыргызстан из Китая вакцины не завозятся. "Мы получаем вакцины из Бельгии, Кореи, Японии, Индии. Только от тех производителей, продукт которых преквалифицирован Всемирной организацией здравоохранения. Это означает, что вакцина безопасна и соответствует международным нормам качества. Кыргызстан заключил меморандум с Детским фондом ООН (ЮНИСЕФ). Закупка вакцин производится только через отдел поставок международной организации", - подчеркнула она.

По словам Ишенапысовой, к примеру, российскую вакцину в Кыргызстан не завозят, так как у нее нет преквалификации ВОЗ.

Есть тема? Пишите Kaktus.media на: +996 (700) 62 07 60
URL: https://kaktus.media/378153Копировать ссылку
Комментарии
дефолтная аватарка юзера
мммда
06.08.2018, 20:44

во первых укажите что за вакцина!? а во вторых у нас уже очень много родителей отказались вакцинировать своих детей и на это есть 2 веских аргумента плохой мед осмотр перед вакцинацией, вакцины не известного происхождения!!! родителей абсолютно не ИНФОРМИРУЮТ о том что колят ребенку, страну изготовителя и тд. одно время поговаривали что вакцины эксперементальные  и особенно опасно колоть АКДС...

ВЕСЬ ПРОЦЕСС ПРОИСХОДИТ ТАК: ПРИХОДИШЬ РАСПИСЫВАЕШСЯ В ТЕТРАДКЕ ТЕБЕ ПОКАЗЫВАЮТ АМПУЛУ С РАСТВОРОМ... И ТВОЕМУ РЕБЕНКУ ДЕЛАЮТ УКОЛ...

ЛИЧНО Я ОТКАЗАЛАСЬ КОЛОТЬ РЕБЕНКА КОГДА УЗНАЛА ЧТО ВАКЦИНА ИНДИЙСКАЯ....ЕСТЬ ЕЩЕ АМЕРИКАНСКАЯ НО ЕЕ ТОЖЕ НЕ ХОЧУ КОЛОТЬ...хотелось бы узнать покупает ли правительство вакцины или они гуманитарные...и значит ли то что вакцины гуманитарные то что качество препарата низкое??? и есть ли центры где можно выбрать вакцину по стране изготовителю? и даже пусть за деньги сделать вакцинацию???

+1
Цитировать
Жалоба модератору
дефолтная аватарка юзера
Куба
07.08.2018, 10:11

Ни названия вакцины, ни даты скандала, ни ссылки на новость. Нет даже ничего кроме того что в одном подъезде одна бабушка сказала что...

А слово чангчунг чангшенг вообще придумала бабушка без фантазии. Ищи потом во всем китае компанию такую.

Вы хоть авторов статей что ли пишите. Мы читатели сами будем знать кто пишет реальность (расследует, старается, работает), а кто сидит и из пальца инф высасывает.

0
Цитировать
Жалоба модератору
дефолтная аватарка юзера
Кубе( Кактус пропустите плз, спсб)
08.08.2018, 18:32

Куба

Ни названия вакцины, ни даты скандала, ни ссылки на новость. Нет даже ничего кроме того что в одном подъезде одна бабушка сказала что...

А слово чангчунг чангшенг вообще придумала бабушка без фантазии. Ищи потом во всем китае компанию такую.

Вы хоть авторов статей что ли пишите. Мы читатели сами будем знать кто пишет реальность (расследует, старается, работает), а кто сидит и из пальца инф высасывает.

в первом абзаце слово "СМИ" нажимаешь и идешь на российский саит читать первоисточник. Или погугли "скандал с прививкои в Китае". Много инфы в интернете.

Или вот читаи, это из китаискои глобалтаимс:

А brewing scandal over violations of drug production regulations by one of China's largest vaccine manufacturers, which has sparked nationwide outrage, could pose serious challenges for a domestic industry that has seen rapid growth in recent years but experienced a series of scandals.

The growing concerns over the safety of the whole domestic vaccine industry, triggered by the Changchun Changsheng incidents, could also turn Chinese consumers to foreign alternatives and prompt tougher regulations. These factors are likely to rein in the skyrocketing profits of domestic companies, experts noted.

The outrage started when the China Food and Drug Administration (CFDA) released a statement on July 15, saying an investigation into Changchun Changsheng Life Sciences found that the company has seriously violated drug production quality management regulations, including forging production records on rabie vanccine. The probe was launched after the CFDA received complaints.

The situation further escalated after the CFDA on July 19 announced penalties on Changsheng resulted from another separate probe into the company launched in November 2017. The company was found selling substandard vaccines back that time.

Finger-pointing continues regarding the Changsheng incident, with some blaming authorities for a lack of proper oversight and others pointing to dishonest companies that only seek profits and ignore the safety of millions of patients across the country.

But experts noted that the key root behind the frequent incident of problematic vaccine is that punishment for companies that violate regulations is too light, prompting some companies to take risks. 

"If regulation is not tough, companies will always seek (to maximize) profits. Unless there's a major problem, companies will cut production costs as much as they can," a Beijing-based expert told the Global Times, speaking on condition of anonymity. 

"If this kind of life and death [violation] could result in the death penalty, companies wouldn't dare do it."

In the case of Changsheng for violations of selling substandard products in October 2017, the company was only fined about 2.58 million yuan ($381,323) in addition to 858,840 yuan being confiscated, according to a Changsheng filing to the Shenzhen Stock Exchange on Thursday.

"The public's distrust of domestic drug companies has only intensified and after this incident, some might actually turn to foreign vaccines instead of domestic ones," Li Tianquan, co-founder of domestic healthcare big data platform yaozh.com told the Global Times on Sunday. "Domestic companies will mostly likely face some of the toughest regulations."

The Chinese vaccine market has grown rapidly in recent years on the strength of increased government support for healthcare and rising parental attention to having children vaccinated, Li noted. As a result, domestic companies have prospered.

Vaccine companies are some of the most profitable enterprises in China, with 52 vaccine-focused companies listed on the A-share market averaging a gross margin of 50 percent in the first quarter of 2018, according to a report in the Beijing News. 

Changsheng's gross margin was the highest, reaching 91.59 percent.

"With all of these producers, it is hard to imagine that they will grow as fast as they have," Li said, while stressing that "the overall environment is good" for the domestic industry's long-term growth. "This goes in the right direction toward better regulations and better-quality vaccines."

Posted in: ECONOMY,COMPANIES,BIZ FOCUS

или вот у chinadaily.com.cn :

President Xi Jinping has demanded immediate and thorough investigation into the country's latest vaccine scandal and severely punish those responsible, while improving the country's vaccine management system to safeguard the bottom line of people's safety.

Xi said in an instruction that the illegal production of vaccines by Changchun Changsheng Bio-tech Company is vile in nature and shocking.

He urged related departments and local governments to pay high attention to the incident and immediately carry out thorough investigation into the facts and ensure those responsible face full force of law.

All information should be released in a timely manner to answer the concerns of the public, he added.

Xi said it is the bounden duty of governments at all levels to ensure drug safety, and the health of the public should be always given top priority.

He demanded the authorities to improve the national vaccine management system with the determination of scraping the poison off the bone and hold the bottom line of safety, sparing no effort to guarantee the vital interests of the public as well as social security and stability.

Changchun police starts probing vaccine producer

Police in Changchun, Jilin province, have launched an investigation into Changchun Changsheng Bio-tech Co, a major vaccine producer in China, for allegedly making substandard rabies vaccines for human use.

Top officials of the company, including the chairwoman surnamed Gao and four other senior executives, were brought to the police bureau for questioning, the police bureau of Changchun New Area said in a press release on Monday evening.

Unannounced inspections

The State Drug Administration will conduct unannounced inspections on all companies that produce vaccines.

According to the Center for Disease Control and Prevention in Shandong, the 252,600 doses of substandard DTaP vaccine sold by Changchun Changsheng Bio-tech were distributed to Jinan, Zibo, Yantai, Jining, Tai'an, Weihai, Rizhao and Laiwu in Shandong. 215,184 children were injected the substandard vaccine.

In Hebei, 143,941 children in Shijiazhuang, Langfang and Dingzhou were given substandard DTaP vaccine produced by Wuhan Institute of Biological Products Co.,Ltd., said the Center for Disease Control and Prevention in Hebei.

Some substandard DTaP vaccines produced by Wuhan Institute of Biological Products Co, Ltd were also distributed to Chongqing, but the Center for Disease Control and Prevention in Chongqing has not yet provided details.

The Centers for Disease Control and Prevention in Shandong, Hebei and Chongqing said they would vaccinate those affected again.

On Monday, shares of vaccine-related companies fell due to the vaccine scandal exposed over the weekend. Shares of Changchun High & New Technology Industries (Group) Inc; Chongqing Zhifei Biological Products Co, Ltd; Shenzhen Kangtai Biological Products Co, Ltd; and Walvax Biotechnology Co, Ltd fell by the daily limit of 10 percent. More than 37 billion yuan was wiped out from 51 shares related to biological vaccines as of 9:40 am. Changsheng Bio-tech Co escaped the beating as it suspended trading on Monday.

Investigation starts on new vaccine scandal

The State Drug Administration has launched an investigation of Changchun Chang­sheng Bio-tech Co, which was found to have fabricated production records for freeze-dried rabies vaccines for human use.

The cases of those suspected of violating laws will be transferred to public security departments, the authority said on Sunday.

Premier Li Keqiang said in an instruction that the vaccine case has crossed a moral line, and the nation deserves a clear explanation, the State Council said on its website on Sunday.

The State Council should immediately send a group to investigate to uncover the truth as soon as possible, and any wrongdoing will be severely punished regardless of who is involved, Li said.

Xu Jinghe, deputy head of the drug administration, said the company was found to have fabricated production and inspection records.

Such activities are in violation of the country’s drug management law and related regulations on drug production, Xu said.

In a notification on July 15, the drug administration ordered the company to stop producing the human rabies vaccine. It said no products involved in the inspection were currently being sold and all the vaccine involved had been removed.

The administration has also revoked the company’s certificate that is needed for production and sales of the vaccine.

The administration confirmed that the company’s other vaccines now available on the market have been tested and no quality problems were found. The administration also launched further tests on the vaccine samples kept by the company.

Its remarks came amid public concerns about vaccine safety in China over the weekend, after it was also revealed that Changsheng Bio-tech was linked to a substandard DTaP vaccine for infants. 

On Friday, the Jilin Provincial Drug Administration announced a penalty regarding Changchun Changsheng Bio-tech Co’s substandard DTaP vaccine.

The company was fined 2.58 million yuan ($282,000), and 859,000 yuan in assets from sales of the vaccine were confiscated.

The case was under investigation last year.

Changsheng Bio-tech Co, parent company of Changchun Changsheng Bio-tech Co, revealed in November that 252,600 doses of the substandard DTaP vaccine that couldn't meet the standard of immunity results were all sold to Shandong province and had been recalled. 

“The substandard DTaP vaccine won’t post safety threats to people’s health, but will reduce the expected immune effects,” Dingxiang­yuan, a professional medical website, said in an online reply to public concerns about the vaccine’s safety. 

The state drug administration confirmed on Sunday that it was discovered in October that one batch of Changsheng’s DTaP vaccine was substandard, and its production of DTaP has been suspended since then.

A plan for reinoculation of those affected was worked out in February.

Several state media called for severe punishment and stricter supervision of vac­cines. People’s Daily released a commentary on Sunday saying that drugmakers should stick to moral principles and make life their priority rather than profits. 

In a news report released on Sunday, the Procuratorate Daily, a publication of the Supreme People’s Procuratorate, called for stronger supervision of vaccine production and tougher penalties for violators. 

The Shenzhen Stock Exchange announced that it sent letters to Changsheng Bio-tech Co on Sunday, calling for early disclosure of the two cases to the public. 

“We will maintain strict supervision over the listed company’s information disclosure responsibility according to the law and guarantee legal rights of investors,” it said in the online announcement. 

The Shenzhen Stock Exchange posted a reply from Changsheng Bio-tech Co later in the afternoon on its website. It says, “We feel very remorseful and guilty about what has happened, and we apologize to all those vaccinated and investors.”

The company added that it will learn a lesson.

Contact the writer at [email protected]

0
Цитировать
Жалоба модератору
дефолтная аватарка юзера
Комментарии от пользователей появляются на сайте только после проверки модератором.
Правила комментирования
На нашем сайте:
  • нельзя нецензурно выражаться
  • нельзя публиковать оскорбления в чей-либо адрес, в том числе комментаторов
  • нельзя угрожать явно или неявно любому лицу, в том числе "встретиться, чтобы поговорить"
  • нельзя публиковать компромат без готовности предоставить доказательства или свидетельские показания
  • нельзя публиковать комментарии, противоречащие законодательству КР
  • нельзя публиковать комментарии в транслите
  • нельзя выделять комментарии заглавным шрифтом
  • нельзя публиковать оскорбительные комментарии, связанные с национальной принадлежностью, вероисповеданием
  • нельзя писать под одной новостью комментарии под разными никами
  • запрещается использовать в качестве ников слова "Кактус", "kaktus", "kaktus.media" и другие словосочетания, указывающие на то, что комментатор высказывается от имени интернет-издания
  • нельзя размещать комментарии, не связанные по смыслу с темой материала
  • нельзя использовать в качестве ника чужое реальное имя и/или фамилию
НАВЕРХ  
НАЗАД